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Abstract 18 
Objective To evaluate the cardiopulmonary and sedative effects of xylazine alone or in 19 
combination with methadone, morphine or tramadol in sheep. 20 
Study design Experimental, prospective, crossover, randomized, blinded study. 21 
Animals Six Santa Inês breed sheep (females) aged 12 ± 8 months and weighing 39.5 ± 7.4 kg. 22 
Methods Sheep were sedated with each of four treatments in a randomized, crossover design, 23 
with a minimum washout period of 7 days between treatments. Treatments were: X [xylazine 24 
(0.1 mg kg–1)]; XM [xylazine (0.1 mg kg–1) and methadone (0.5 mg kg–1)]; XMO [xylazine 25 
(0.1 mg kg–1) and morphine (0.5 mg kg–1)], and XT [xylazine (0.1 mg kg–1) and tramadol 26 
(5 mg kg–1)]. Each drug combination was mixed in the syringe and injected intravenously. 27 
Sedation, heart rate (HR), mean arterial blood pressure (MAP), rectal temperature (RT °C), 28 
respiratory rate (fR), arterial blood gases and electrolytes were measured before drug 29 
administration (T0) and then at 15 minute intervals for 120 minutes (T15–T120). 30 
Results Heart rate significantly decreased in all treatments compared with T0. PaCO2 values in 31 
XM and XMO were higher at all time points compared with T0. In treatments X and XM, pH, 32 
bicarbonate (HCO3−) and base excess were increased at all time points compared with T0. PaO2 33 
was significantly decreased at T15–T75 in XM, at all time points in XMO, and at T15 and T30 in 34 
XT. Sedation at T15 and T30 in XM and XMO was greater than in the other treatments. 35 
Conclusions and clinical relevance The combinations of methadone, morphine or tramadol 36 
with xylazine resulted in cardiopulmonary changes similar to those induced by xylazine alone in 37 
sheep. The combinations provided better sedation, principally at 15 minutes and 30 minutes 38 
following administration. 39 
 40 
Keywords α2-agonists, opioids, ovine, sedation. 41 
 42 
Introduction 43 
Xylazine is 10–20 times more potent in ruminants than in other species (Kästner 2006). 44 
Cardiopulmonary effects include bradycardia, changes in arterial blood pressure, tachypnea 45 
accompanied by pulmonary edema and arterial hypoxemia (Bacon et al. 1998; Kästner 2006). 46 
Death resulting from the development of pulmonary edema after administration of xylazine has 47 
also been reported (Uggla & Lindqvist 1983). Despite these profound cardiopulmonary effects, 48 
sedation may not be as pronounced as expected, and recumbency may not be induced when 49 
xylazine is administered to sheep intravenously (IV) or intramuscularly (IM) (Kästner 2006). 50 
Therefore, combining xylazine with other drugs may be useful to enhance sedation. 51 
Morphine and methadone are classified as full µ-agonists and are widely used in veterinary 52 
practice, alone or in combination with other drugs for premedication and analgesia. However, the 53 
reported use of these drugs in ruminants is rare. Studies on drug residues are lacking, which may 54 
limit the clinical usefulness of opioids in food animal practice (KuKanich & Papich 2009). 55 
Tramadol may be classified as an atypical opioid drug because much of its analgesic action is 56 
attributable to a central effect in inhibiting the reuptake of serotonin and noradrenaline, and it 57 
also shows relatively weak action at opioid µ-receptors (KuKanich & Papich 2009). Adverse 58 
effects following its administration include sedation, although there are few data on its 59 
administration as part of a premedication or sedation protocol in sheep. Guedes et al. (2005) 60 
demonstrated that tramadol alone administered IM to dogs prior to general anesthesia did not 61 
produce any visible sedation. Excitatory effects on the central nervous system (CNS), such as 62 
agitation and nystagmus, following the administration of opioids to ruminants have been 63 
described (Waterman et al. 1990, 1991; Lin & Riddell 2003; Edmondson et al. 2012), and may 64 
counteract the level of sedation observed. 65 
Combinations of sedatives and opioid drugs are commonly used in veterinary anesthesia because 66 
they have useful synergistic effects. This synergism enhances sedation and analgesia and may 67 
facilitate a significant reduction in the doses of both drugs, thereby reducing the adverse 68 
cardiopulmonary effects associated with each drug when it is administered alone. Numerous 69 
studies in dogs and cats have demonstrated that sedation is better when an α2-agonist is 70 
administered in combination with an opioid than when the α2-agonist is administered alone 71 
(Selmi et al. 2003; Leppänen et al. 2006; Monteiro et al. 2008; Cardoso et al. 2014). 72 
The aim of this study was to examine the cardiopulmonary and sedative effects of xylazine in 73 
combination with different opioids when administered IV in sheep. The study hypothesis was 74 
that sedation would be superior following the administration of these combinations compared 75 
with the administration of xylazine alone. 76 
Materials and methods 77 
This research was conducted with the approval and supervision of the Ethics Committee on 78 
Animal Use of the University of Franca, Brazil (protocol no. 038/12). All procedures were 79 
conducted in compliance with the ethical principles of good practice in animal experimentation. 80 
Animals 81 
Six female, non-pregnant Santa Inês sheep, with a mean ± standard deviation (SD) age of 82 
12 ± 8 months and mean ± SD weight of 39.5 ± 7.4 kg were used. The animals were kept 83 
collectively in 6 × 6 m plots and were given hay, pelleted feed and mineral supplements on a 84 
daily basis, and water ad libitum. Prior to the study, the health of the animals was evaluated 85 
using a complete blood count, liver and renal biochemical profile, and fecal parasitologic 86 
examination. For at least 20 days prior to the initiation of the study, the animals were monitored 87 
for individual behavior and were conditioned to physical restraint. Before the study, food and 88 
water were withheld for 24 hours and the hair over the right jugular vein and auricular arteries 89 
was clipped. 90 
Once the animals were moved to the experimental area, the skin sites for vessel catheterization 91 
were aseptically prepared. A catheter (18 gauge, 2.5 cm Safelet; Nipro Medical Ltda, SP, Brazil) 92 
was introduced into the right jugular vein, and a second catheter (20 gauge, 2.5 cm) introduced 93 
into an auricular artery with the sheep restrained in a standing position. The ambient temperature 94 
was 22 °C. Fifteen minutes were allowed to elapse following instrumentation before any 95 
measurements were recorded. 96 
Experimental design 97 
The sheep were randomized (by drawing of lots) to four treatments in a crossover study, with a 98 
minimum interval of 7 days between treatments. The four treatments were: X, xylazine 99 
(0.1 mg kg–1; Rompun 2%; Bayer AG, SP, Brazil); XM, xylazine (0.1 mg kg–1) and methadone 100 
(0.5 mg kg–1; Mytadon, 10 mg mL–1; Cristália Produtos Químicos e Farmacêuticos Ltda, SP, 101 
Brazil); XMO, xylazine (0.1 mg kg–1) and morphine (0.5 mg kg–1; Dimorf, 10 mg mL–1; Cristália 102 
Produtos Químicos e Farmacêuticos Ltda), and XT, xylazine (0.1 mg kg–1) and tramadol 103 
(5 mg kg–1; Tramadon, 50 mg mL–1; Cristália Produtos Químicos e Farmacêuticos Ltda). Each 104 
drug combination was mixed in the syringe. The final volume was adjusted to 5 mL with 0.9% 105 
sodium chloride to facilitate blinding and administered IV into the jugular catheter over 106 
30 seconds. The catheter was then flushed with 0.9% sodium chloride. Animals were then left to 107 
wander freely in the experiment area. Data for all variables were collected by the same 108 
investigator for all animals at all evaluation times. Variables were measured before drug 109 
administration (baseline, T0) and every 15 minutes after drug administration for 120 minutes 110 
(T15–T120). 111 
Degree of sedation 112 
Three evaluators who were unaware of the treatment assessed the degree of sedation. Sedation 113 
was scored using a numerical rating scale of 0–10, on which a score of 0 indicates no sedation 114 
and a score of 10 indicates recumbency with no movement (Kästner et al. 2003) (Appendix 1). 115 
Assessments of sedation were always performed prior to the measurement of other variables and 116 
evaluators’ scores were averaged. 117 
Cardiopulmonary variables 118 
Cardiopulmonary data were collected in the following order. Heart rate (HR) was measured 119 
using transthoracic auscultation with a stethoscope in the region of the fourth left intercostal 120 
space for 1 minute. Mean arterial blood pressure (MAP) was evaluated using the arterial catheter 121 
connected to a system filled with 0.1% heparin solution (50 IU mL–1). Pressure was measured 122 
intermittently using an aneroid manometer (Indústria Bic de Aparelhos Médicos Ltda, SP, 123 
Brazil) which was calibrated against a mercury column before use. Prior to measurement, the 124 
system was zeroed using the air–saline junction at the point of the shoulder in standing and 125 
sternally recumbent animals and the xiphoid process in laterally recumbent animals as reference 126 
points. Respiratory rate (fR) was assessed by observing the movements of the thorax for 127 
1 minute. Rectal temperature (RT °C) was measured with a clinical mercury-in-glass 128 
thermometer (Thermometer BD; Becton Dickinson Indústrias Cirurgicas SA, MG, Brazil) 129 
inserted into the rectum. Arterial blood samples were taken from the arterial catheter for 130 
determination of pH, arterial partial pressure of carbon dioxide (PaCO2), arterial partial pressure 131 
of oxygen (PaO2), base excess (BE), arterial hemoglobin oxygen saturation (SaO2), sodium 132 
(Na+), potassium (K+), ionized calcium (iCa2+) and chloride (Cl−) concentrations. Each blood 133 
sample amounted to 0.5 mL and was withdrawn into a disposable syringe containing heparin and 134 
sealed with a rubber stopper. Samples were analyzed immediately using a blood gas analyzer 135 
[Cobas b 121; Roche Diagnostics (Schweiz) AG, Switzerland]. 136 
Statistical analysis 137 
Data were analyzed using GraphPad Prism Version 5.0 (GraphPad Software, Inc., CA, USA). 138 
Data were tested for normality prior to analysis using the Shapiro–Wilk test. Normally 139 
distributed data were analyzed using analysis of variance (ANOVA) for repeated measures; 140 
Dunnett’s test was used to compare data within the same treatment group. ANOVAs and a post 141 
hoc Tukey test were used to compare data between treatments. Non-parametric data were 142 
analyzed using the Kruskal–Wallis test with a post hoc Dunn’s test. For all analyses, a p-value of 143 
< 0.05 was considered to indicate statistical significance. 144 
Results 145 
All animals were included in the study and all completed the 120 minute evaluation period, 146 
recovering without complications. Behavioral effects other than sedation included drooling, 147 
bruxism, vocalization and facial or generalized tremors (Table 1). 148 
Sedative effects 149 
Sedation scores were significantly higher compared with baseline at T15–T105 in X (p < 0.01) 150 
and at T15–T90 in XM (p < 0.001) and at all time points in XMO (p < 0.01) and XT (p < 0.001) 151 
(Fig. 1). In XM, sedation was significantly greater at T15 in comparison with T90, T105 and 152 
T120 (p < 0.01). In XMO, sedation scores were significantly greater at T15, T30 and T60 in 153 
comparison with T105 and T120. In XT, sedation at T30 was significantly greater than at T120. 154 
When sedation scores were compared between treatments, those at T15 and T30 were 155 
significantly higher in XM and XMO than in X and XT. At T30, the sedation score in XT was 156 
significantly higher than in X (p < 0.05). 157 
Sternal or lateral recumbency (scores 6–10) occurred in variable numbers of animals in XM at 158 
three time points (T15, T30, T45), in XMO at six time points (T15–T90) and in XT at three time 159 
points (T15, T60, T90). Recumbency was not observed in any animal administered xylazine 160 
alone. 161 
Cardiopulmonary variables and body temperature 162 
Heart rate decreased in all treatments at all time points in comparison with baseline (p < 0.001) 163 
(Table 2). There was no significant difference in HR among treatments. MAP was significantly 164 
decreased from baseline in X at T45 and T90 (p < 0.05) and in XMO at T15 (p < 0.0001), T45 165 
and T75 (p < 0.001) and T60 (p < 0.05). In XT, MAP was significantly higher at T15 and T75 166 
than in the other treatments. 167 
Rectal temperatures were unchanged, except at T60 in X (p < 0.05), and did not differ among 168 
treatments. 169 
In comparison with baseline values, fR was significantly lower at T60–T120 in X (p < 0.05) and 170 
T45–T90 in XMO (p < 0.001) (Table 2). There were no significant differences among 171 
treatments. 172 
Blood gas and electrolyte variables 173 
Significant increases in pH compared with baseline were measured at all time points in X and 174 
XM, and at T45–T120 in XMO (p < 0.001) (Table 3). In a comparison among treatments, pH 175 
values in X and XM were significantly higher at T45 and T120. PaCO2 values were higher at all 176 
time points than at baseline (p < 0.001) in XM and XMO. In the comparative analysis among the 177 
treatments, no significant difference was observed. Analysis of BE revealed a significant 178 
increase (values became more positive) at all time points compared with T0 in X and XM 179 
(p < 0.0001), and at T30–T120 in XMO and XT (p < 0.05). There were no statistically 180 
significant differences among treatments. 181 
In comparison with baseline values, PaO2 was significantly lower at T15–T75 in XM (p < 0.01), 182 
at all time points in XMO (p < 0.001), and at T15 and T30 in XT (p < 0.001). In comparison with 183 
values in treatment X, PaO2 values were significantly lower at T30–T60 in XM (p < 0.01), T15 184 
in XMO (p < 0.01) and T30 in XT (p < 0.05). 185 
There were no statistically significant differences in values of SaO2, Na+, K+, iCa2+ and Cl– in 186 
either comparisons with baseline values or among treatments, and values remained within the 187 
physiologic ranges for this species. 188 
Discussion 189 
The combination of a sedative (such as an α2-agonist) with an opioid is used very commonly in 190 
veterinary anesthetic practice. Recommended doses of xylazine for IV administration to sheep 191 
vary markedly. Grant & Upton (2001) found that 0.05 mg kg–1 of xylazine IM resulted in poor 192 
sedation, whereas administration of 0.1 mg kg–1 xylazine IM resulted in obvious signs of 193 
sedation, but the animals remained standing (Shokry et al. 1976). Marked sedative effects were 194 
observed at doses of > 0.3 mg kg–1 IV (Hsu et al. 1987, 1989). A dose of 0.1 mg kg–1 xylazine 195 
was chosen for this study in order to achieve sedation sufficient for comparison with the effects 196 
of xylazine–opioid combinations. 197 
Equipotent doses of morphine, methadone and tramadol for sheep are not reported in the 198 
literature. Consequently, the dose rates used in this study were based on those in studies that 199 
compared the use of morphine with tramadol or methadone in dogs (Mastrocinque & Fantoni 200 
2003; Maiante et al. 2009). 201 
The time course of 120 minutes chosen for this study was based on what is known about the 202 
pharmacokinetic characteristics of xylazine in sheep (Garcia-Villar et al. 1981) and the sedative 203 
effects of morphine, methadone and tramadol in combination with dexmedetomidine in dogs 204 
(Cardoso et al. 2014). 205 
Adverse side effects such as tremors, bruxism, nystagmus and vocalization were prevalent in all 206 
the xylazine–opioid treatments. Waterman et al. (1990, 1991) demonstrated that butorphanol and 207 
fentanyl administration in sheep leads to agitation and distressed behavior. Lin & Riddell (2003) 208 
observed slow horizontal nystagmus following IV administration of detomidine and butorphanol 209 
in dairy cattle. In the same species, sedation after the administration of xylazine and butorphanol 210 
was no greater than that after xylazine alone (Levine et al. 1992). Alpacas exhibited neurologic 211 
signs of hyperexcitability, hyperesthesia, tremors and ataxia after administration of tramadol IV 212 
(Edmondson et al. 2012). The adverse effects observed in the present study were similar, further 213 
supporting the excitatory effects of opioids on the CNS in ruminant species. 214 
Following the IV administration of α2-agonists, there is a biphasic blood pressure response. 215 
Initially, hypertension caused by peripheral vasoconstriction occurs, after which a reflex 216 
bradycardia is mediated by baroreceptors. In humans, a prolonged, centrally mediated 217 
hypotensive period then ensues, but hypotension after the administration of α2-agonists has not 218 
been reported in dogs (Murrell & Hellebrekers 2005). In sheep, the administration of xylazine 219 
(0.05 mg kg–1 IM or 0.2 mg kg–1 IV) did not induce significant changes in HR (Bacon et al. 220 
1998; Grant & Upton 2001). Opioids can cause cardiovascular depression by inducing negative 221 
chronotropy and decreased cardiac output (Stanley et al. 1980). However, in goats, 0.6 mg kg–1 222 
methadone IV did not cause alterations in HR for up to 240 minutes (Olsén et al. 2013). 223 
Similarly, in dogs, the administration of morphine at 3 mg kg–1 IV did not induce significant 224 
changes in HR during 30 minutes of evaluation (Priano & Vatner 1981). IV tramadol at doses of 225 
1.5 mg kg–1 and 2.6 mg kg–1 followed by a continuous infusion caused no change in HR in dogs 226 
over 45 minutes (Seddighi et al. 2009). The effects of combinations of an α2-agonist with an 227 
opioid on MAP have not been described in sheep. In dogs administered xylazine and methadone, 228 
systolic arterial blood pressure fell but hypotension did not occur over the 60 minute study 229 
period (Monteiro et al. 2008). In the present study, although MAP was significantly decreased at 230 
some time points, hypotension (MAP < 60 mmHg) was not observed. HR decreased during all 231 
treatments, but at no time was clinically significant bradycardia noted. 232 
The administration of α2-agonists may result in a decrease in body temperature caused by 233 
depression of the thermoregulatory centre (Pypendop & Verstegen 1998) and reduced muscular 234 
activity (Virtanen 1989). In the present study, the significant decrease in the RT of sheep 235 
identified at one time point after xylazine administration was not clinically significant, and no 236 
significant decreases in RT occurred in the other treatments. Administration of methadone 237 
(0.5 mg kg–1 and 1 mg kg–1 IV) and morphine (1 mg kg–1 IV) to dogs resulted in a progressive 238 
reduction of body temperature for up to 90 minutes (Maiante et al. 2009). Monteiro et al. (2009) 239 
reported that body temperature decreased in dogs administered tramadol 2 mg kg–1 IV and 240 
acepromazine, although the vasodilatory effects of acepromazine are likely to be responsible for 241 
this change. 242 
Dexmedetomidine and medetomidine administered to sheep do not change fR (Kästner et al. 243 
2001). PaCO2 was not significantly changed after IV administration of 0.15 mg kg–1 and 244 
0.2 mg kg–1 xylazine to sheep (Celly et al. 1997; Bacon et al. 1998), despite the occurrence of 245 
apnea for 30 seconds followed by tachypnea for up to 60 minutes (Celly et al. 1997). Opioids 246 
may cause respiratory depression by decreasing the ventilatory response to hypercapnia (Steffey 247 
et al. 1993); however, hypercapnia did not occur after the administration of morphine or 248 
methadone (0.5 mg kg–1) IV to conscious dogs (Maiante et al. 2009). There is evidence that 249 
tramadol has little effect on ventilation in some species when administered at doses lower than 250 
those used in this study (Mastrocinque & Fantoni 2003). In the present study, fR decreased 251 
significantly at 60–120 minutes in X and 45–120 minutes in XMO, and mild but statistically 252 
significant increases in PaCO2 were observed in the XM and XMO treatments for the duration of 253 
monitoring. Sedation with treatment XM resulted initially in lateral recumbency and with XMO 254 
in sternal recumbency, which may have limited lung expansion and resulted in decreased 255 
ventilation. 256 
Determination of pH can be used as an indicator of homeostasis (Sobiech et al. 2005). The pH 257 
and BE values in all treatments showed a progressive increase with time. Elevations of pH, 258 
bicarbonate (HCO3−) and BE have been reported following epidural xylazine in sheep (Aminkov 259 
& Hubenov 1995) and IV xylazine in goats (Mogoa et al. 2000), although none of these authors 260 
suggested why these changes occurred. Ringer et al. (2013) analyzed the acid-base and 261 
electrolyte effects of a continuous 3 hour infusion of romifidine or xylazine in horses and noted 262 
increasing pH, HCO3− and BE. The authors hypothesized that this change was attributable to 263 
hypochloremia resulting from urinary loss. No significant electrolyte abnormalities were 264 
identified in the present study and therefore the mechanism by which such changes occur in 265 
sheep remains uncertain. 266 
Hypoxemia [PaO2 < 60 mmHg (7.9 kPa)] in sheep after administration of an α2-agonist is 267 
common, especially when the drug is administered IV (Kästner 2006). The proposed mechanism 268 
of action is intense venous spasm mediated via adrenoreceptor agonism, intense pulmonary 269 
congestion, increased microvascular pressure and alveolar capillary rupture, resulting in an 270 
inflammatory response (Celly et al. 1997; Bacon et al. 1998; Kästner et al. 2007). As previously 271 
discussed, opioids may cause respiratory depression (Steffey et al. 1993), leading to hypoxemia, 272 
particularly when the animal is breathing atmospheric air. However, in dogs, the administration 273 
of methadone or morphine at the same doses used in this study did not induce changes in PaO2 274 
(Maiante et al. 2009). Likewise, tramadol 2 mg kg–1 did not cause alterations in PaO2 in dogs 275 
(Mastrocinque & Fantoni 2003). In this study, PaO2 was decreased, particularly when 276 
combinations of xylazine and an opioid were administered, and these changes were statistically 277 
significant. This decrease may reflect the level of sedation as sheep administered a xylazine–278 
opioid combination were more likely to become recumbent, which may have adverse effects on 279 
ventilation perfusion matching. Mitchell & Williams (1976) measured arterial oxygen 280 
concentrations in healthy, conscious sheep and found them to be significantly lower in laterally 281 
recumbent than in standing animals. However, in the present study, at no point did the decrease 282 
in PaO2 translate to a clinically significant decrease in SaO2. It must be emphasized that oxygen 283 
should be provided to sedated sheep if possible, particularly when the animal is at greater risk for 284 
hypoxemia from lateral or dorsal positioning, is unfasted or has systemic disease. 285 
In conclusion, opioids used in combination with xylazine in sheep potentiate the sedative effect 286 
of xylazine in a similar way to that described in other species; methadone and morphine appear 287 
to promote better sedation. As the number of animals included in this study was small, and the 288 
doses of drugs were restricted, further work is necessary to ascertain the most suitable 289 
combination for clinical use. The combinations depressed HR in a manner similar to that induced 290 
by xylazine alone, but MAP was maintained. Although PaO2 was reduced in all treatments, SaO2 291 
values did not indicate the need for oxygen therapy. 292 
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Appendix 1  Numerical rating scale for assessment of sedation in sheep (Kästner et al. 2003) 392 
Score Behavior 
0 Standing, alert, normal behavior 
1 Standing, alert, reduced head and ear movements 
2 Standing, slight head drop 
3 Standing, moderate head drop 
4 Standing, severe head drop and ataxia 
5 Standing, severe head drop and severe ataxia 
6 Sternal recumbency, head up 
7 Sternal recumbency, unable to support head 
8 Lateral recumbency, occasional attempts to attain sternal recumbency 
9 Lateral recumbency, uncoordinated head and leg movements 
10 Lateral recumbency, no movements 393 
Figure 1  Sedation scores in six sheep after intravenous administration of (a) xylazine 394 
(0.1 mg kg–1) (X), (b) xylazine (0.1 mg kg–1) and methadone (0.5 mg kg–1) (XM), (c) xylazine 395 
(0.1 mg kg–1) and morphine (0.5 mg kg–1) (XMO) or (d) or xylazine (0.1 mg kg–1) and tramadol 396 
(5 mg kg–1) (XT). Sedation scores of ≥ 6 indicate sternal recumbency and scores of ≥ 8 indicate 397 
lateral recumbency. Lines indicate median scores, boxes indicate interquartile ranges and 398 
whiskers indicate ranges. *Significantly different from baseline within the same treatment (X 399 
and XMO: p < 0.01; XM and XT: p < 0.001). †Significantly different from X and XT at the 400 
same time point (p < 0.05). ‡Significantly different from X at the same time point (p < 0.05). 401 402 
Table 1  Adverse effects observed in six sheep over 120 minutes in four treatment conditions: 403 
intravenous (IV) xylazine (0.1 mg kg–1) (treatment X); IV xylazine (0.1 mg kg–1) and methadone 404 
(0.5 mg kg–1) (treatment XM); IV xylazine (0.1 mg kg–1) and morphine (0.5 mg kg–1) (treatment 405 
XMO), and IV xylazine (0.1 mg kg–1) and tramadol (5 mg kg–1) (treatment XT) 406 
NB, normal behavior. 407 408 Treatment Time points (minutes) 
T15 T30 T45 T60 T75 T90 T1   
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Table 2  Mean ± standard deviation heart rate (HR), mean arterial pressure (MAP), rectal 409 
temperature (RT °C) and respiratory rate (fR) in sheep before (T0) and after intravenous 410 
administration of xylazine (X), xylazine and methadone (XM), xylazine and morphine (XMO) or 411 
xylazine and tramadol (XT) 412 
 Treatment Time points (minutes) 
T0 T15 T30 T45 T60 T75 T90 T105  
 
 e–1) 
X 101 ± 14 85 ± 11* 73 ± 14* 71 ± 17* 70 ± 16* 74 ± 14* 75 ± 16* 77 ± 9*    
XM 124 ± 14 70 ± 11* 77 ± 14* 78 ± 15* 86 ± 16* 83 ± 14* 88 ± 9* 92 ± 9*    
XMO 112 ± 12 77 ± 15* 78 ± 13* 73 ± 7* 71 ± 9* 72 ± 7* 79 ± 9* 90 ± 14*    
XT 105 ± 13 70 ± 9* 71 ± 9* 69 ± 12* 71 ± 12* 77 ± 15* 76 ± 16* 84 ± 19    
 
 
X 110 ± 11 99 ± 11 99 ± 7 97 ± 14* 98 ± 8 103 ± 9 95 ± 12* 99 ± 10    
XM 103 ± 10 93 ± 9 92 ± 8 94 ± 14 99 ± 12 97 ± 9 99 ± 7 99 ± 12    
XMO 111 ± 14 89 ± 11* 99 ± 8 94 ± 12* 97 ± 13* 93 ± 12* 104 ± 6 104 ± 10    
XT 109 ± 8 107 ± 9† 106 ± 6 110 ± 15 114 ± 12 115 ± 12† 106 ± 17 111 ± 13    
 
 
X 39.1 ± 0.5 39.2 ± 0.4 39.0 ± 0.4 38.9 ± 0.5 38.8 ± 0.6 38.9 ± 0.5 38.9 ± 0.6 39.1 ± 0.7    
XM 39.3 ± 0.4 39.1 ± 0.5 38.9 ± 0.6 38.9 ± 0.7 39.0 ± 0.8 39.2 ± 0.8 39.3 ± 0.7 39.5 ± 0.7    
XMO 39.7 ± 0.6 39.6 ± 0.7 39.4 ± 0.6 39.2 ± 0.6 39.2 ± 0.5 39.3 ± 0.4 39.4 ± 0.4 39.4 ± 0.4    
XT 39.3 ± 0.3 39.4 ± 0.8 39.1 ± 0.6 39.0 ± 0.6 39.0 ± 0.7 38.8 ± 0.7 38.9 ± 1.0 39.2 ± 0.8    
 
 ute–1) 
X 28 ± 7 27 ± 11 25 ± 10 24 ± 11 21 ± 6* 20 ± 5* 21 ± 6* 19 ± 7*    
XM 23 ± 10 21 ± 5 18 ± 4 23 ± 7 19 ± 5 18 ± 4 19 ± 4 19 ± 2    
XMO 28 ± 6 24 ± 5 24 ± 8 20 ± 4* 21 ± 2* 19 ± 4* 21 ± 3* 22 ± 8    
XT 26 ± 4 29 ± 9 25 ± 12 21 ± 7 21 ± 8 24 ± 10 20 ± 7 20 ± 4    
*Significantly different from T0 within the same treatment (p < 0.05). †Significantly different 413 
from other treatments at the same time point (p < 0.05). 414 415 
Table 3  Mean ± standard deviation arterial pH (pH), arterial partial pressure of carbon dioxide 416 
(PaCO2), arterial partial pressure of oxygen (PaO2), bicarbonate (HCO3–) and base excess (BE) 417 
in sheep sedated with xylazine (X), xylazine and methadone (XM), xylazine and morphine 418 
(XMO) or xylazine and tramadol (XT) 419 
 atment Time points (minutes) 
T0 T15 T30 T45 T60 T75 T90 T105  
  7.46 ± 0.02  7.50 ± 0.02* 7.52 ± 0.01* 7.53 ± 0.02*† 7.52 ± 0.04*† 7.54 ± 0.03*† 7.52 ± 0.02*† 7.53 ± 0.03     
 7.45 ± 0.06 7.48 ± 0.03* 7.50 ± 0.03* 7.51 ± 0.02*† 7.52 ± 0.02*† 7.53 ± 0.03*† 7.52 ± 0.04*† 7.53 ± 0.03     
O 7.41 ± 0.08 7.44 ± 0.06 7.46 ± 0.04 7.49 ± 0.03* 7.50 ± 0.03* 7.52 ± 0.02* 7.51 ± 0.02* 7.51 ± 0.02     
 7.47 ± 0.07 7.48 ± 0.06 7.50 ± 0.04 7.51 ± 0.03 7.51 ± 0.04 7.52 ± 0.03 7.51 ± 0.04 7.51 ± 0.03    
 
 
 32 ± 3 33 ± 3 34 ± 2 35 ± 3 33 ± 3 32 ± 2 34 ± 3 33 ± 3    
 29 ± 3 35 ± 1* 36 ± 3* 37 ± 1* 36 ± 3* 34 ± 2* 34 ± 1* 34 ± 3*    
O 28 ± 3 32 ± 2* 33 ± 3* 33 ± 2* 33 ± 3* 32 ± 3* 34 ± 3* 33 ± 2*    
 31 ± 3 34 ± 4 34 ± 4 34 ± 3 35 ± 3 34 ± 2 35 ± 4 32 ± 5    
 
 
 4.2 ± 0.4 4.3 ± 0.4 4.5 ± 0.2 4.6 ± 0.4 4.3 ± 0.4 4.2 ± 0.2 4.5 ± 0.4 4.3 ± 0.4    
 3.8 ± 0.4 4.6 ± 0.1* 4.7 ± 0.4* 4.9 ± 4.9* 4.7 ± 0.4* 4.5 ± 0.2* 4.5 ± 0.1* 4.5 ± 0.4*    
O 3.7 ± 0.4 4.2 ± 0.2*  4.3 ± 0.4* 4.3 ± 0.2* 4.3 ± 0.4* 4.2 ± 0.4* 4.5 ± 0.4* 4.3 ± 0.2*    
 4.1 ± 0.4 4.5 ± 0.5  4.5 ± 0.5 4.5 ± 0.4 4.6 ± 0.4 4.5 ± 0.2 4.6 ± 0.5 4.3 ± 0.6    
 
 
 80 ± 3 71 ± 10 73 ± 6 75 ± 5 77 ± 10 75 ± 9 77 ± 3 73 ± 3    
 81 ± 4 65 ± 8*† 65 ± 8*† 65 ± 8*† 69 ± 6* 71 ± 7* 76 ± 6 75 ± 5    
O 84 ± 3 63 ± 6*† 70 ± 5* 73 ± 7* 67 ± 5* 73 ± 3* 73 ± 5* 75 ± 8*     
 81 ± 1 64 ± 10* 64 ± 6*† 74 ± 5 75 ± 4 76 ± 5 74 ± 5 73 ± 6    
  10.6 ± 0.4 9.4 ± 1.3 9.7 ± 0.7 9.9 ± 0.6 10.2 ± 1.3 9.9 ± 1.1 10.2 ± 0.3 9.7 ± 0.3    
  10.7 ± 0.5 8.6 ± 1.0*† 8.6 ± 1.0*† 8.6 ± 1.0*† 9.1 ± 0.7* 9.4 ± 0.9* 10.1 ± 0.7 9.9 ± 0.6    
O 11.1 ± 0.4 8.3 ± 0.7*† 9.3 ± 0.6* 9.7 ± 0.9* 8.9 ± 0.6* 9.7 ± 0.3* 9.7 ± 0.6* 9.9 ± 1.0*    
 10.6 ± 0.1 8.5 ± 1.3* 8.5 ± 0.7*† 9.8 ± 0.6* 9.9 ± 0.5 10.1 ± 0.6 9.8 ± 0.6 9.7 ± 0.7    
 
  
 21 ± 2 25 ± 2* 27 ± 3* 28 ± 2* 28 ± 4* 27 ± 3* 27 ± 3* 27 ± 3*    
 20 ± 3 26 ± 2* 27 ± 2* 29 ± 1* 29 ± 2* 28 ± 2* 27 ± 2* 27 ± 2*    
O 23 ± 2 22 ± 4 23 ± 4  25 ± 3 25 ± 2 26 ± 2 26 ± 3* 26 ± 1    
 22 ± 5 25 ± 4* 26 ± 4* 27 ± 3* 27 ± 4* 27 ± 3* 27 ± 4* 25 ± 4    
 
  
 − 2 ± 2 2 ± 1* 4 ± 2* 5 ± 2* 5 ± 4* 5 ± 3* 4 ± 2* 4 ± 2*    
 − 3 ± 4 2 ± 2* 4 ± 2* 6 ± 1* 6 ± 2* 5 ± 2* 4 ± 3* 4 ± 2*    
O − 5 ± 4 − 2 ± 5 0 ± 4* 2 ± 3* 2 ± 3* 3 ± 2* 3 ± 2* 3 ± 1*    
 − 1 ± 6 2 ± 4 4 ± 4* 4 ± 3* 5 ± 3* 4 ± 3* 4 ± 4* 3 ± 3*    
*Statistically different from T0 within the same treatment (p < 0.05). †Statistically different from 420 
all other treatments at the same time point (p < 0.05). 421 
